Recommendations supporting respiratory syncytial virus vaccines marketed by Pfizer (NYSE:PFE) and GSK (NYSE:GSK) made last ...

The advisory panel to the Centers for Disease Control and Prevention had made recommendations regarding the use of separate ...

Pfizer (PFE) stock draws public scrutiny as a House probe gathers new allegations regarding the company's COVID-19 vaccine ...

An FDA panel of experts has recommended approval of Pfizer’s respiratory syncytial virus (RSV) vaccine in a pair of ... s RSVPreF3 jab will come under the scrutiny of the VRBPAC later today ...

Both subgroups cause disease and can co-circulate or alternate predominance from season to season. Pfizer currently is the only company with an RSV vaccine to help protect adults aged 60 and older, ...

A committee of independent vaccine experts ... the vote on the use of RSV vaccines in people in their 50s would initially apply to vaccines sold by GSK and Pfizer. Moderna is in the process ...

Key products like cardiovascular treatment Vyndaqel and the Prevnar 13 vaccine continue to drive growth, with non-COVID sales up 11% in the quarter. Pfizer’s pipeline is robust, with RSV vaccine ...

Only one tenth of hospitalized adults aged 60 years or older received the respiratory syncytial virus (RSV) vaccine during its ... such as Moderna Inc, Pfizer Inc, AstraZeneca, Regeneron ...

ABOUT ABRYSVO Pfizer currently is the only company with an RSV vaccine to help protect adults aged 60 and older, and adults 18 and older at increased risk of lower respiratory tract disease caused ...